BH-30236

BlossomHill Therapeutics · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BH-30236
Sponsor	BlossomHill Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BH-30236 CI brief — competitive landscape report
BH-30236 updates RSS · CI watch RSS
BlossomHill Therapeutics portfolio CI